As per the expression of interest sought by the Indian Council for Medical Research (ICMR), Department of Health Research (DHR), government of India, close to38 technologies targeted for 2013-14, can be commercialized to achieve few of its affordable healthcare goals.

These technologies include the diagnostic assays, reagents, devices for Diabetes Mellitus; Cervical Cancer; and Thalassemia. Apart from that recombinant vaccine for Hepatitis E vaccine and combination of Hepatitis E & Hepatitis B vaccines using a novel approach. Also on the list is a recombinant protein- based assay for diagnosis of hepatitis E. The technologies targeting the various infectious diseases like Tuberculosis, Leptospirosis, Hepatitis E, Rotavirus Diarrhea, food borne pathogens, Chlamydia Infections, Kalazar, Malaria, Filaria and Lung Fluke infection, are also available for commercialization.

Under the nutrition category, ICMR institutes have created the assays for bioavailability of Iron, Vitamin A estimation. Among other technologies that are available include are cooling garment to prevent and manage heat effects; ergonomically designed rickshaw; test for determination of viability of sperms; molecules, metabolites /organisms for biological control of mosquitoes/ vectors.
The ICMR is looking forward to the receive proposals for the technologies developed by its institutes, from the companies upto May 31, 2013.

This strategy to bring the public lab research to the industry table by the India's medical regulator, can be seen as an effective step towards public private partnership for affordable healthcare.